Search clinical trials for: Bevacizumab

Total 2439 results

Genentech, Inc.

Completed

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Metastatic Colorectal Cancer
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Australia
Brigham and Women's Hospital

Completed

Angiogenic Imaging in Pulmonary Arterial Hypertension (AIPAH)

Pulmonary Arterial Hypertension | Exercise Associated Pulmonary Arterial Hypertension

United States
University of Southern California

Completed

Avastin for PDR (Proliferative Diabetic Retinopathy) (PDR)

Diabetic Retinopathy | Retinal Detachment

United States
Instituto de Oftalmología Fundación Conde de Valenciana

Completed

Bevacizumab for Primary Pterygium Treatment

Pterygium

Mexico
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (BASKETⅡ)

Colorectal Cancer | Immunotherapy

China
Reza Dana, MD

Completed

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Corneal Neovascularization | Corneal Graft Failure

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo

Unknown

Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. (BECOX)

Metastatic Colorectal Cancer

Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8 | Ampulla of Vater Adenocarcinoma | Stage III Ampulla... and other conditions

United States
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Colorectal Cancer

China
Sun Yat-sen University

Completed

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Federico II University

Completed

Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab

Exudative Age-related Macular Degeneration

Italy
Toni Choueiri, MD
Beth Israel Deaconess Medical Center

Completed

Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Sivakami A Pai

Unknown

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.

United Arab Emirates
Asociación para Evitar la Ceguera en México

Unknown

Effect of Avastin in Juxtafoveal Telangiectasias

Telangiectasis

Mexico
Enrico De Toni

Recruiting

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC)

Hepatocellular Carcinoma

Germany
Sun Yat-sen University

Recruiting

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Lung Adenocarcinoma | PD-1 Inhibitor | Stage IV Non-small Cell Lung Cancer | VEGF
Yongchang Zhang

Recruiting

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Non Small Cell Lung Cancer

China
Shandong University

Recruiting

Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Objective Response Rate

China
Wills Eye

Completed

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions? (Avastin)

Glaucoma

United States
Genentech, Inc.

Completed

A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Universidad Autonoma de San Luis Potosí

Unknown

Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1 (Bevacizumab)

Retinopathy of Prematurity

Mexico
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Lymphoproliferative Disorder

United States
Memorial Sloan Kettering Cancer Center

Completed

Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Laboratorios Liomont
Servicios Especializados en Ensayos Clínicos, S.C.

Recruiting

Safety of Effivia®, a Bevacizumab Biosimilar

Metastatic Colorectal Cancer | Metastatic Cervical Cancer | Non Squamous Non Small Cell Lung Cancer

Mexico
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Ovarian Cancer
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Glioblastoma

China
Henan Cancer Hospital
Qilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.

Not yet recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

HER-2 Negative Breast Cancer
CHA University
Hoffmann-La Roche

Completed

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Advanced Hepatocellular Carcinoma

Korea, Republic of
Pfizer

Withdrawn

A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

Pharmacokinetics

China
Center Eugene Marquis

Completed

Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients (AVA-CELL)

Glioma | Glioblastoma

France
Indiana University
Genentech, Inc.

Completed

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

Neoplasms, Germ Cell and Embryonal

United States
Hoffmann-La Roche

Completed

Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin) (CONCERT)

Metastatic Colorectal Cancer

France
Providence Health & Services
Bristol-Myers Squibb; Genentech, Inc.

Terminated

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-squamous Non-small Cell Lung Cancer

United States
Sanofi

Completed

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Neoplasms, Malignant

France, United Kingdom, Italy
National Center for Tumor Diseases, Heidelberg
Pfizer; Roche Pharma AG

Terminated

Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (APRIORI)

Colorectal Carcinoma

Germany
Hallym University Medical Center

Completed

Major and Macular Branched Retinal Venous Occlusion

Macular Edema

Korea, Republic of
Asociación para Evitar la Ceguera en México

Unknown

POSTERIOR SUB-TENON'S Avastin

Diffuse Diabetic Macular Edema

Mexico
Reza Dana, MD
United States Department of Defense; New York Presbyterian Hospital; Bascom Palmer...

Completed

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Corneal Neovascularization | Corneal Graft Failure

United States
University of Utah
Genentech, Inc.

Completed

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

Cancer

United States
Si-Yu Wang

Completed

Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma

Lung Cancer

China
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
Sun Yat-sen University

Not yet recruiting

TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria (B-TACE)

Hepatocellular Carcinoma by BCLC Stage

China
Second Affiliated Hospital of Nanchang University
Zhejiang University

Not yet recruiting

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Glioblastoma

Search clinical trials for: Bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations